title: Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women.
abstract: OBJECTIVE
  To compare changes in the concentrations of Lp(a) lipoprotein and other atherogenic lipids and lipoproteins in natural and hyperstimulated ovarian cycles.
  
  
  METHODS
  Open, prospective study.
  
  
  METHODS
  Academic department in a teaching hospital.
  
  
  METHODS
  Normal ovulatory women served as controls and the treatment group consisted of women undergoing ovarian hyperstimulation.
  
  
  METHODS
  The treatment group received hMG on a fixed regimen.
  
  
  METHODS
  Measurements of serum lipids and lipoproteins were made in both natural and hyperstimulated cycles.
  
  
  RESULTS
  There was a significant increase in the median concentration of Lp(a) lipoprotein from 10.1 to 10.7 mg/dL in the luteal compared with the proliferative phase of unstimulated cycles. In hyperstimulated cycles, there was a significant increase in the median concentration of Lp(a) lipoprotein from 9.7 mg/dL in the proliferative phase to 11.3 mg/dL in the luteal phase. Reductions in concentrations of total cholesterol and low-density lipoprotein cholesterol were found in the luteal phase of hyperstimulated cycles.
  
  
  CONCLUSIONS
  Concentrations of Lp(a) lipoprotein increase during the luteal phase of both natural and hyperstimulated ovarian cycles.
authors.affiliation: Prince of Wales Hospital, Chinese University of Hong Kong, Department of Obstetrics and Gynaecology, Shatin, New Territories, Hong Kong. CJOHNHAINES@CUHK.EDU.HK
authors.forename: C J
authors.initials: CJ
authors.lastname: Haines
authors.forename: L P
authors.initials: LP
authors.lastname: Cheung
authors.forename: C W
authors.initials: CW
authors.lastname: Lam
mesh_terms: D000328:Adult; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008183:Luteal Phase / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000009:adverse effects / Q000627:therapeutic use; D008597:Menstrual Cycle; D010062:Ovulation Induction / Q000009:adverse effects*; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D008055:Lipids; D017270:Lipoprotein(a); D008074:Lipoproteins; D014280:Triglycerides; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone